QUALITY OF LIFE IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS IN THE CONDITIONS OF TREATMENT WITH CHIMERIC MONOCLONAL ANTIBODIES TO TNF α

QUALITY OF LIFE IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS IN THE CONDITIONS OF TREATMENT WITH CHIMERIC MONOCLONAL ANTIBODIES TO TNF α

Show other versions (1)

The article presents results of study of inhibitor TNF α — infliximab — on quality of life in patients with juvenile arthritis, refractory to standard immunosuppressive treatment. In 1.5 months after the beginning of treatment, the quality of life increased in 98% of patients; and in one year, the r...

Full description

Bibliographic Details
Main Authors: R.V. Denisova, E.I. Alexeeva, V.Yu. Al'bitsky, I.V. Vinyarskaya, S.I. Valieva
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2009-05-01
Series:Вопросы современной педиатрии
Online Access:https://vsp.spr-journal.ru/jour/article/view/1113
Description
Summary:The article presents results of study of inhibitor TNF α — infliximab — on quality of life in patients with juvenile arthritis, refractory to standard immunosuppressive treatment. In 1.5 months after the beginning of treatment, the quality of life increased in 98% of patients; and in one year, the rates of physical functioning were similar to it in healthy children the same age.Key words: children, juvenile arthritis, quality of life, infliximab.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(3):18-26)
ISSN:1682-5527
1682-5535

Similar Items